Regentis Biomaterials is an Israeli regenerative-medicine issuer whose entire listed case sits on GelrinC, a cell-free hydrogel implant for focal knee cartilage injuries. The first-half print covering the period ended mid-year shows a still pre-revenue company carrying a going-concern warning while it tries to finish a United States pivotal study that slipped from a mid-year close into a year-end close. What changed is not the science so much as the clock. Enrollment is now more than halfway done, Europe is moving from CE Mark paperwork into surgeon training, and a June private placement rebuilt cash after the December listing leftover proved too thin.
The financing is the real first-half event. ThinkEquity placed ordinary shares and five-year warrants at a deep discount to the listing price, adding roughly two million new shares against a mid-year count near seven million. Cash ended the half near nine million after the company repaid its remaining insider loans and used about three million in operations. That cash covers enrollment and a thin European start, not a two-year follow-up plus a premarket approval filing plus a United States launch. The market already treats the residual claim as an option on GelrinC rather than a going franchise.
Management now guides full enrollment of the eighty-patient SAGE study around year-end rather than the third quarter, and the annual filing still records substantial doubt about continuity. The next stretch of reporting resolves whether site activation can close the remaining cohort without another emergency raise, and whether European Centers of Excellence produce any paid procedures before the premarket clock even starts. If enrollment finishes and cash lasts into late next year, the equity is a cheap call on a CE-marked implant. If recruitment stalls again, the same cash math that forced the June placement repeats at a lower price.